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ABOUT THE COVER
The reassessment of prostate cancer surgical specimens led to
reclassification of standard prognostic variables in 15% of cases, including
modification of the pathological stage. The radical prostatectomy from this
patient with biochemical relapse after surgery was initially classified as
pt2, but showed after review a focal extraprostatic extension, with a tumor
focus adjacent to periprostatic adipose tissue, beyond the rounded
boundary of the gland. For further details, please see Fromont and
co-workers on page 836 in this issue.
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